Evidence, grade of recommendation and level of agreement for each recommendation
| Item | Category of evidence | Grade of recommendation | Level of agreement (mean±SD) |
|---|---|---|---|
| A | NA | NA | 8.9±0.3 |
| B | NA | NA | 8.4±1.1 |
| C | NA | NA | 8.5±0.9 |
| 1 | 1b*, 4 | A, D | 8.4±1.1 |
| 2 | 1b, 3† | A, C | 8.6±0.7 |
| 3 | 1b‡, 3§ | A, C | 8.1±0.9 |
| 4 | 2b | B | 8.1±0.9 |
| 5 | 1b | A | 8.2±0.9 |
| 6 | 3 | C | 8.8±0.5 |
| 7 | 3 | C | 8.6±0.7 |
| 8 | 1b¶, 2b** | A, B | 8.8±0.4 |
| 9 | 3 | C | 8.8±0.4 |
| 10 | 1b | A | 8.2±1.3 |
| 11 | 3 | C | 8.2±0.9 |
Ranking for category of evidence and grade of recommendation is provided in the online supplementary material.
*For the evidence that colchicine should be given as early as possible, within 12 hours of symptom onset.
†There are no randomised controlled trials of intra-articular corticosteroid injections for flares.
‡Level of evidence for canakinumab.
§For ankinra.
¶Level of evidence for febuxostat and allopurinol.
**For uricosurics (probenecid or benzbromarone).
NA, not applicable.